Kura Oncology Inc (KURA)vsRevolution Medicines Inc (RVMD)
KURA
Kura Oncology Inc
$8.74
-0.34%
HEALTHCARE · Cap: $802.08M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Kura Oncology Inc generates 9555% more annual revenue ($71.64M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. KURA earns a higher WallStSmart Score of 28/100 (F).
KURA
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 29.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KURA
The strongest argument for KURA centers on Debt/Equity, Revenue Growth. Revenue growth of 29.5% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : KURA
The primary concerns for KURA are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
KURA profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
KURA is growing revenue faster at 29.5% — sustainability is the question.
KURA generates stronger free cash flow (-86M), providing more financial flexibility.
Bottom Line
KURA scores higher overall (28/100 vs 24/100) and 29.5% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kura Oncology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?